Apalutamide in Metastatic Castration-Sensitive Prostate Cancer (mCSPC): A Case-Based Discussion
Release Date: 05/31/2024
2026 National Quality Improvement Initiative: Timely Administration of Intravesical Chemotherapy Post-TURBT
AUANews Inside Tract
Join Drs. Minhaj Siddiqui, Kristen Scarpato, and Chad Ritch as they discuss an exciting opportunity to participate in a national quality improvement project sponsored by the American College of Surgeons (ACS) Cancer Programs to improve timely administration of intravesical chemotherapy post-TURBT (TaPT). Time is limited to engage in this opportunity – the intent to participate in the TaPT Quality Improvement Collaborative is due to the ACS by February 15, 2026. To learn more about the opportunity, visit and consider advocating with your institution to participate.
info_outline
Igniting Discovery: Arcus Medical’s Journey Through AUA Innovation Nexus
AUANews Inside Tract
What does it take to turn a clinical idea into a scalable medical device? In this AUANews Insight Tract episode, Dr. Hugo Davila and Dr. Raul Storey of Arcus Medical reflect on their experience as participants in the AUA Innovation Nexus Boot Camp. They explore how Nexus connects physicians, entrepreneurs, and industry experts to help overcome common startup challenges, including FDA pathways, IP protection, reimbursement, and investor engagement. Discover how this physician-driven accelerator is transforming urology innovation and enabling founders to bring their ideas from concept to care.
info_outline
SAU/AUA Urology Match Insider: The Power of Mentorship
AUANews Inside Tract
Developed by the Society of Academic Urologists in partnership with the American Urological Association, the SAU/AUA Urology Match Insider series provides medical students interested in the field of urology an inside look into the Urology Residency Match process. In this episode, medical student, Lola Lozano, sits down with Dr. Sara Lenherr and Dr. Adam Weiner to discuss the power of mentorship, including best practices for students seeking a mentor, key attributes of a successful mentorship relationship, and lessons learned from past mentee-mentor experiences.
info_outline
Inside Urology Practice Journal: A Conversation with the New Editorial Leadership
AUANews Inside Tract
In this episode of AUANews Inside Tract, UPJ's new Editor-in-Chief, Dr. Kathleen Kobashi, and Associate Editor, Dr. Gina Badalato, share their vision for the future of Urology Practice. They discuss the journal’s unique role in delivering practical, education-focused research, evolving article types, emerging topics like AI, and how readers can engage as authors and reviewers.
info_outline
QIPS Insights: Opioid Prescribing After PCNL
AUANews Inside Tract
Quality Improvement and Patient Safety In this episode, Dr. Kevin Koo joins Dr. Andrew Harris, Chair of AUA’s Quality Improvement and Patient Safety (QIPS) Committee, for a conversation on opioid prescribing practices and patient-reported pain outcomes following percutaneous nephrolithotomy (PCNL). They discuss the development and implementation of a tailored opioid prescribing algorithm that reduced unnecessary prescriptions, ensured adequate pain management, and highlighted the importance of multimodal analgesia in postoperative care.
info_outline
Capital Stream: Inside the AUA’s 2025 Advocacy Wins
AUANews Inside Tract
Join Josh Webster and Dr. Mark Edney as they break down the AUA’s most significant health policy victories of 2025. From the historic removal of the FDA’s black box warning on low-dose estrogen to progress on Medicare payment reform, NIH research funding, prior authorization relief, telehealth expansion, and prostate cancer screening advocacy, 2025 was a big year for the AUA. This special AUANews Inside Tract episode brings listeners inside the halls of Congress, highlights the AUA’s growing influence in federal and state policy, outlines what’s next, and how members can stay engaged...
info_outline
AUA Census Trends: Burnout, Mental Health, and Barriers to Care in Urology
AUANews Inside Tract
In this episode of AUANews Inside Tract, Census Trends, Dr. Catherine Nam and Dr. Hannah Glick explore key findings from the AUA Census on burnout among urologists, with nearly half reporting symptoms of stress. They discuss unhealthy coping mechanisms, the stigma around seeking mental health care, and how licensure policies may discourage physicians from getting help. The episode also offers actionable steps for physicians, administrators, and policymakers to support well-being and shift the culture around mental health in medicine.
info_outline
Global Perspectives: Insights from India
AUANews Inside Tract
In this episode of Global Perspectives, Dr. Niels Johnsen and Dr. George Koch share their firsthand experiences as AUA Academic Exchange Scholars in India. From clinical insights to cultural discoveries, they reflect on the lessons learned, the surprises encountered, and the lasting impact of international collaboration on their approach to urology.
info_outline
Training Transformed: University of Minnesota
AUANews Inside Tract
Developed by the AUA Residents and Fellows Committee, each episode of the Training Transformed podcast series features an interview with a urology faculty member and resident physician surrounding an innovative facet of resident education at their institution. Tune in for our next episode as moderator, Dr. Samuel Ivan, chats with Drs. Philipp Dahm, Lane Shish and Pooja Srikanth about the University of Minnesota’s international partnership and exchange program with the University of Helsinki.
info_outline
Celebrating 50 Years of AUA Research
AUANews Inside Tract
In this episode of AUANews Inside Tract, we celebrate 50 years of research support in urology. Since 1975, the AUA and the Urology Care Foundation have awarded nearly $40 million to over 1,000 researchers, driving innovation and improving care for millions of patients. Host Dr. Damara Kaplan sits down with Dr. Glenn Preminger, a distinguished AUA Research Scholar alumnus and pioneer in kidney stone management and minimally invasive surgery, to reflect on the legacy of AUA research, explore his groundbreaking career, and look ahead to the future of urologic innovation.
info_outlineThis podcast “Apalutamide in Metastatic Castration-Sensitive Prostate Cancer (mCSPC): A Case-Based Discussion” was originally presented as an AUA newsworthy webinar and contains data regarding the clinical efficacy and safety of apalutamide. It is presented on behalf of Janssen and is not certified for CME; speakers were compensated. For full details, see the video webinar here.
TITAN, a Phase 3 double-blind study, randomized patients with metastatic castration-sensitive prostate cancer (mCSPC) to apalutamide (Apa; 240 mg oral once daily) + androgen deprivation therapy (ADT; n=525) or placebo + ADT (n=527).1,2 All patients received a concomitant gonadotropin-releasing hormone analog or had prior bilateral orchiectomy.3 Patients who received prior treatment for localized disease or received but did not progress on docetaxel were permitted. Dual primary endpoints were radiographic progression-free survival and overall survival (OS).1,2
At primary analysis (median follow-up: 22.7 months), Apa + ADT reduced the risk of radiographic progression or death by 52% vs placebo + ADT (HR: 0.48; 95% CI: 0.39–0.60). Apa + ADT also reduced the risk of death by 33% vs placebo + ADT (HR: 0.67; 95% CI: 0.51–0.89).1 At primary analysis cutoff, TITAN was unblinded and 39.5% of patients who received placebo + ADT crossed over to receive Apa + ADT; these patients were analyzed as part of the placebo + ADT population in the intent-to-treat analyses. The IPCW log-rank test was performed to account for crossover and showed a 48% reduction in the risk of death for Apa + ADT vs placebo + ADT (HR: 0.52; 95% CI: 0.42–0.64). At final analysis (median follow-up: 44.0 months), Apa + ADT reduced the risk of death by 35% vs placebo + ADT (median OS: NE vs 52.2 months; HR: 0.65; 95% CI: 0.53–0.79).
In a prespecified subgroup analysis, Apa + ADT improved OS vs placebo + ADT, regardless of disease volume. In patients with high-volume disease, Apa + ADT reduced the risk of death by 30% vs placebo + ADT (HR: 0.70; 95% CI: 0.56–0.88); for low-volume disease, Apa + ADT reduced the risk of death by 48% vs placebo + ADT (HR: 0.52; 95% CI: 0.35–0.79).2
The following post hoc analyses data are not included in the full ERLEADA® (apalutamide) Prescribing Information.
Post hoc exploratory analyses investigated PSA kinetics.4,5 After 3 months of Apa treatment, median OS was not reached in patients with a PSA response. In patients without a PSA response, median OS was 37.7 months.5 Most Apa + ADT-treated patients had undetectable PSA at 3 months. By 12 months, 64% of Apa-treated patients had undetectable PSA vs 23% of patients treated with placebo + ADT.5
Please see the full Prescribing Information for ERLEADA® (apalutamide) at www.erleadahcp.com.
- Chi KN, et al. N Engl J Med. 2019;381:13–24.
- Chi KN, et al. J Clin Oncol. 2021;39:2294–2303.
- ERLEADA® (apalutamide) [Prescribing Information]. Horsham, PA: Janssen Biotech, Inc.
- Chowdhury S, et al. Ann Oncol. 2023;34:477–485.
- Chi KN, et al. Presented at AUA; September 10–13, 2021; Las Vegas, Nevada.